DaVita reports Q2 results on August 4 with short sellers pulling back and analysts chasing the stock higher — yet the price has already moved well past most targets on the Street.
The short interest picture has shifted meaningfully in recent weeks. Bears have covered ground, with short interest falling roughly 8% over the past month to 6.3% of the free float, or about 4.5 million shares. Borrow conditions remain loose — availability runs above 500%, meaning there are roughly five shares available to lend for every one already borrowed — so there is no friction forcing that covering. Cost to borrow ticked up 43% over the past week but remains negligible at under 0.5%. Options positioning is mildly elevated but not extreme: the put/call ratio of 0.62 sits just above its 20-day average, roughly one standard deviation above the mean, suggesting traders have added a modest hedge but are not bracing for a sharp move. The stock itself has climbed 8% over the past month to close at $240.09, carrying momentum into the print.
Analysts have been scrambling to keep up. UBS raised its target to $270 and Truist lifted its to $250 in mid-July, both maintaining existing ratings — a catch-up in conviction rather than a directional pivot. Barclays moved its target to $218 on July 9, still well below the current price. The consensus mean sits near $209, which the stock has already surpassed by about 15%, a gap that concentrates the debate on whether the Q2 print can justify the re-rating. Bulls point to DaVita's dominant 35% US market share in dialysis, stable Medicare-anchored revenue, and the implicit endorsement of Berkshire Hathaway's near-45% stake. Bears flag the asymmetric profit structure — commercial insurers generate a disproportionate share of earnings despite covering only 10% of patients — and the ongoing risk of reimbursement pressure squeezing margins. The forward P/E of roughly 14.7x and EV/EBITDA near 10x are not demanding multiples, but earnings momentum factor scores rank in the 75th-82nd percentile, suggesting the consensus has already priced in improving estimates.
The insider picture adds one cautionary note. CEO Javier Rodriguez sold over 69,000 shares across two days in mid-June for combined proceeds near $14.5 million, with the CLO and CFO also selling in May and June. The sales came at prices well below the current level, so they do not necessarily signal a top — but the consistent pattern of C-suite selling throughout the rally is worth noting heading into a report where the stock has little analyst cover above it.
The August 4 print is less a test of whether DaVita's business is stable and more a test of whether Q2 earnings power can close the gap between where the stock trades and where analysts think it belongs.
See the live data behind this article on ORTEX.
Open DVA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
